Advertisement
| clinical trial technology companies: Neuroscience Trials of the Future National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2016-11-07 On March 3-4, 2016, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop in Washington, DC, bringing together key stakeholders to discuss opportunities for improving the integrity, efficiency, and validity of clinical trials for nervous system disorders. Participants in the workshop represented a range of diverse perspectives, including individuals not normally associated with traditional clinical trials. The purpose of this workshop was to generate discussion about not only what is feasible now, but what may be possible with the implementation of cutting-edge technologies in the future. |
| clinical trial technology companies: Sharing Clinical Trial Data Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Responsible Sharing of Clinical Trial Data, 2015-04-20 Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients. |
| clinical trial technology companies: Virtual Clinical Trials National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2019-11-16 Successful drug development relies on accurate and efficient clinical trials to deliver the best and most effective pharmaceuticals and clinical care to patients. However, the current model for clinical trials is outdated, inefficient and costly. Clinical trials are limited by small sample sizes that do not reflect variations among patients in the real world, financial burdens on participants, and slow processes, and these factors contribute to the disconnect between clinical research and clinical practice. On November 28-29, the National Academies of Sciences, Engineering, and Medicine convened a workshop to investigate the current clinical trials system and explore the potential benefits and challenges of implementing virtual clinical trials as an enhanced alternative for the future. This publication summarizes the presentations and discussions from the workshop. |
| clinical trial technology companies: Envisioning a Transformed Clinical Trials Enterprise in the United States Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2012-09-13 There is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and practical evidence for drug development and to support medical treatment decisions. With the need for transforming the CTE in the U.S. becoming more pressing, the IOM Forum on Drug Discovery, Development, and Translation held a two-day workshop in November 2011, bringing together leaders in research and health care. The workshop focused on how to transform the CTE and discussed a vision to make the enterprise more efficient, effective, and fully integrated into the health care system. Key issue areas addressed at the workshop included: the development of a robust clinical trials workforce, the alignment of cultural and financial incentives for clinical trials, and the creation of a sustainable infrastructure to support a transformed CTE. This document summarizes the workshop. |
| clinical trial technology companies: Transforming Clinical Research in the United States Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation, 2010-10-22 An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise. |
| clinical trial technology companies: Cool Companies:Medical Devices & Technologies in Alberta, Canada 2010 Claudia Sammer, 2010 |
| clinical trial technology companies: Sharing Clinical Research Data Institute of Medicine, Board on Health Care Services, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, National Cancer Policy Forum, Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, 2013-06-07 Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advances derived from data pooling and analysis could improve public health, enhance patient safety, and spur drug development. Data sharing can also increase public trust in clinical trials and conclusions derived from them by lending transparency to the clinical research process. Much of this information, however, is never shared. Retention of clinical research data by investigators and within organizations may represent lost opportunities in biomedical research. Despite the potential benefits that could be accrued from pooling and analysis of shared data, barriers to data sharing faced by researchers in industry include concerns about data mining, erroneous secondary analyses of data, and unwarranted litigation, as well as a desire to protect confidential commercial information. Academic partners face significant cultural barriers to sharing data and participating in longer term collaborative efforts that stem from a desire to protect intellectual autonomy and a career advancement system built on priority of publication and citation requirements. Some barriers, like the need to protect patient privacy, pre- sent challenges for both sectors. Looking ahead, there are also a number of technical challenges to be faced in analyzing potentially large and heterogeneous datasets. This public workshop focused on strategies to facilitate sharing of clinical research data in order to advance scientific knowledge and public health. While the workshop focused on sharing of data from preplanned interventional studies of human subjects, models and projects involving sharing of other clinical data types were considered to the extent that they provided lessons learned and best practices. The workshop objectives were to examine the benefits of sharing of clinical research data from all sectors and among these sectors, including, for example: benefits to the research and development enterprise and benefits to the analysis of safety and efficacy. Sharing Clinical Research Data: Workshop Summary identifies barriers and challenges to sharing clinical research data, explores strategies to address these barriers and challenges, including identifying priority actions and low-hanging fruit opportunities, and discusses strategies for using these potentially large datasets to facilitate scientific and public health advances. |
| clinical trial technology companies: Clinical Trials Timothy M. Pawlik, Julie A. Sosa, 2020-03-10 This extensively revised second edition is a unique and portable handbook focusing on clinical trials in surgery. It includes new educational materials addressing the rapid evolution of novel research methodologies in basic science, clinical and educational research. The underlying principles of clinical trials, trial design, the development of a study cohort, statistics, data safety, data monitoring, and trial publication for device and drug trials are also discussed. Clinical Trials provides a comprehensive resource on clinical trials in surgery and describes all the stages of a clinical trial from generating a hypothesis through to trial publication and is a valuable resource for all practicing and trainee academic surgeons. |
| clinical trial technology companies: The Influence of the Pharmaceutical Industry Great Britain: Parliament: House of Commons: Health Committee, 2005-04-26 Incorporating HC 1030-i to iii. |
| clinical trial technology companies: Conflict of Interest in Medical Research, Education, and Practice Institute of Medicine, Board on Health Sciences Policy, Committee on Conflict of Interest in Medical Research, Education, and Practice, 2009-09-16 Collaborations of physicians and researchers with industry can provide valuable benefits to society, particularly in the translation of basic scientific discoveries to new therapies and products. Recent reports and news stories have, however, documented disturbing examples of relationships and practices that put at risk the integrity of medical research, the objectivity of professional education, the quality of patient care, the soundness of clinical practice guidelines, and the public's trust in medicine. Conflict of Interest in Medical Research, Education, and Practice provides a comprehensive look at conflict of interest in medicine. It offers principles to inform the design of policies to identify, limit, and manage conflicts of interest without damaging constructive collaboration with industry. It calls for both short-term actions and long-term commitments by institutions and individuals, including leaders of academic medical centers, professional societies, patient advocacy groups, government agencies, and drug, device, and pharmaceutical companies. Failure of the medical community to take convincing action on conflicts of interest invites additional legislative or regulatory measures that may be overly broad or unduly burdensome. Conflict of Interest in Medical Research, Education, and Practice makes several recommendations for strengthening conflict of interest policies and curbing relationships that create risks with little benefit. The book will serve as an invaluable resource for individuals and organizations committed to high ethical standards in all realms of medicine. |
| clinical trial technology companies: The Routledge Companion to Technology Management Tugrul Daim, Marina Dabić, Yu-Shan Su, 2022-08-31 Bringing together an international range of expertise, this comprehensive Companion to Technology Management is designed to facilitate the development of management frameworks adaptable for a wide range of organizations, as well as an overview of the development and integration of technology in advanced and emerging economies. Research-based and drawing on a range of practical tools and international cases, it covers the diverse spectrum of the challenges of technology management and how to approach them: I Fundamentals of Technology Management provides an overview of the fundamental aspects of technology management. II Technology Planning focusses on technology-driven organizations, government labs and universities. III Technology Evaluation includes evaluation and assessment, adoption and forecasting through management tools. IV Technology Development and Transfer includes integration, marketing and intellectual property management. V Managing Technological Innovations addresses policy, open innovation and technology entrepreneurship. VI Society and Technology Management focusses on social issues which impact technology and its management. VII New Technologies and Emerging Regions includes blockchain, biotechnologies and smart cities. This Companion is an essential comprehensive source of new and emerging approaches for researchers and advanced students in engineering and technology management, as well as professionals seeking an authoritative global reference source. |
| clinical trial technology companies: Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade World Intellectual Property Organization, 2013 This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies. |
| clinical trial technology companies: Improving and Accelerating Therapeutic Development for Nervous System Disorders Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2014-02-06 Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials. |
| clinical trial technology companies: House of Commons - Science and Technology Committee: Clinical Trials - HC 104 Great Britain: Parliament: House of Commons: Science and Technology Committee, 2013-09-17 Many of the trials taking place today are unregistered and unpublished, meaning that the information that they generate remains invisible to both the scientific community and the public. This undermines public trust, slowing the pace of medical advancement and potentially putting patients at risk. All trials conducted on NHS treatments-and all other trials receiving public funding-should be prospectively registered and their results published in a scientific journal. While the focus should be on implementing this change for future trials, the Government must also do what it can to ensure that historic trials are registered and published, particularly where they have been publically funded. The Government should also take steps to facilitate greater sharing of the raw data generated during a trial in a responsible and controlled way, with the knowledge and consent of patients. The report also draws attention to the recent fall in the number of trials taking place in the UK. It finds that the need for multiple governance approvals from participating NHS organisations remained the biggest barrier to setting up a UK trial, but that lack of public awareness was also a key issue. Recruiting participants can also be a challenge. The report calls on the Government to take its recommendations into account in ongoing discussions regarding the revision of European clinical trials legislation and in its response to the European Medicines Agency's consultation on the release of clinical trial data, which closes at the end of this month |
| clinical trial technology companies: Plunkett's Biotech & Genetics Industry Almanac Jack W. Plunkett, 2008-09 A complete market research guide to the business of biotech, genetics, proteomics and related services--a tool for strategic planning, competitive intelligence, employment searches, or financial research. Complete profiles of nearly 400 leading biotech companies, in-depth chapters on trends. Includes glossary thorough indexes, statistics, research and development, emerging technology--as well a addresses, phone numbers, and executive names. |
| clinical trial technology companies: Applications of Machine Learning Prashant Johri, Jitendra Kumar Verma, Sudip Paul, 2020-05-04 This book covers applications of machine learning in artificial intelligence. The specific topics covered include human language, heterogeneous and streaming data, unmanned systems, neural information processing, marketing and the social sciences, bioinformatics and robotics, etc. It also provides a broad range of techniques that can be successfully applied and adopted in different areas. Accordingly, the book offers an interesting and insightful read for scholars in the areas of computer vision, speech recognition, healthcare, business, marketing, and bioinformatics. |
| clinical trial technology companies: Innovation in Clinical Trial Methodologies Peter Schueler, 2020-11-20 Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic presents a selection of updated chapters from Re-Engineering Clinical Trials that feature innovative options and methods in clinical trials. The Coronavirus pandemic is an accelerator for digitalization in many industries, including clinical trials. This book considers best practices, alternative study concepts requiring fewer patients, studies with less patient interaction, the design of virtualized protocols, and moving from data to decisions. This book will be helpful to pharmacologists, physicians and clinical researchers involved in the process of clinical development and clinical trial design. Considers multiple digital and virtual strategies Explores best practices, including the use of reduced patient involvement Brings together expert, trusted information to increase the efficiency and effectiveness of clinical trials |
| clinical trial technology companies: Plunkett's Outsourcing & Offshoring Industry Almanac: Outsourcing and Offshoring Industry Market Research, Statistics, Trends & Leading Companies Jack W. Plunkett, 2007-07 Contains trends, statistical tables, and an industry glossary. This almanac presents over 300 profiles of outsourcing and offshoring industry firms. It also includes addresses, phone numbers, and executives. |
| clinical trial technology companies: New Medical Technology , 1992 |
| clinical trial technology companies: Hospital Group Purchasing United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust, Competition Policy, and Consumer Rights, 2005 |
| clinical trial technology companies: Medical Image Registration Joseph V. Hajnal, Derek L.G. Hill, 2001-06-27 Image registration is the process of systematically placing separate images in a common frame of reference so that the information they contain can be optimally integrated or compared. This is becoming the central tool for image analysis, understanding, and visualization in both medical and scientific applications. Medical Image Registration provid |
| clinical trial technology companies: Valuations of Early-Stage Companies and Disruptive Technologies Tiran Rothman, 2020-11-27 This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration. |
| clinical trial technology companies: Trends and Innovations in Information Systems and Technologies Álvaro Rocha, Hojjat Adeli, Luís Paulo Reis, Sandra Costanzo, Irena Orovic, Fernando Moreira, 2020-06-07 This book gathers selected papers presented at the 2020 World Conference on Information Systems and Technologies (WorldCIST’20), held in Budva, Montenegro, from April 7 to 10, 2020. WorldCIST provides a global forum for researchers and practitioners to present and discuss recent results and innovations, current trends, professional experiences with and challenges regarding various aspects of modern information systems and technologies. The main topics covered are A) Information and Knowledge Management; B) Organizational Models and Information Systems; C) Software and Systems Modeling; D) Software Systems, Architectures, Applications and Tools; E) Multimedia Systems and Applications; F) Computer Networks, Mobility and Pervasive Systems; G) Intelligent and Decision Support Systems; H) Big Data Analytics and Applications; I) Human–Computer Interaction; J) Ethics, Computers & Security; K) Health Informatics; L) Information Technologies in Education; M) Information Technologies in Radiocommunications; and N) Technologies for Biomedical Applications. |
| clinical trial technology companies: Plunkett's Consulting Industry Almanac 2007: Consulting Industry Market Research, Statistics, Trends & Leading Companies Jack W. Plunkett, Plunkett Research Ltd, 2007-06 Covers trends in consulting in such fields as marketing, information technology, management, logistics, supply chain, manufacturing and health care. This guide contains contacts for business and industry leaders, industry associations, Internet sites and other resources. It also includes statistical tables, an industry glossary and indexes. |
| clinical trial technology companies: Clinical Technologies: Concepts, Methodologies, Tools and Applications Management Association, Information Resources, 2011-05-31 This multi-volume book delves into the many applications of information technology ranging from digitizing patient records to high-performance computing, to medical imaging and diagnostic technologies, and much more-- |
| clinical trial technology companies: Oxford Textbook of Pediatric Pain Bonnie J. Stevens, Gareth Hathway, William T. Zempsky, 2021 The oxford textbook of paediatric pain brings together clinicians, educators, trainees and researchers to provide an authoritative resource on all aspects of pain in infants, children and youth. |
| clinical trial technology companies: Business Modeling for Life Science and Biotech Companies Alberto Onetti, Antonella Zucchella, 2014-03-21 Most books on the biotechnology industry focus on scientific and technological challenges, ignoring the entrepreneurial and managerial complexities faced bio-entrepreneurs. The Business Models for Life Science Firms aims to fill this gap by offering managers in this rapid growth industry the tools needed to design and implement an effective business model customized for the unique needs of research intensive organizations. Onetti and Zucchella begin by unpacking the often-used ‘business model’ term, examining key elements of business model conceptualization and offering a three tier approach with a clear separation between the business model and strategy: focus, exploring the different activities carried out by the organization; locus, evaluating where organizational activities are centered; and modus, testing the execution of the organization’s activities. The business model thus defines the unique way in which a company delivers on its promise to its customers. The theory and applications adopt a global approach, offering business cases from a variety of biotech companies around the world. |
| clinical trial technology companies: Plunkett's Almanac of Middle Market Companies: Middle Market Research, Statistics & Leading Companies Jack W. Plunkett, 2007-07 Plunkett's Almanac of Middle Market Companies 2008 is designed to be time-saving business development tool for professionals, marketers, sales directors, consultants and strategists seeking to understand and reach middle market American companies. It will also be of great use to placement, recruiting and human resources professionals, as well as professionals working in economic development, lending and media. It covers competitive intelligence, market research and business analysis--everything you need to identify and develop strategies for middle market corporations. Coverage includes all major business sectors, from InfoTech to health care to telecommunications and much more. (We have intentionally omitted retail companies and banks.) These profiles and details on over 500 middle market firms are pulled from our extensive company and industry databases. We also include a business glossary and a listing of business contacts, such as industry associations and government agencies. Next, we profile hundreds of leading middle market companies. Our company profiles include complete business descriptions and up to 27 executives by name and title. Purchasers of either the book or PDF version can receive a free copy of the company profiles database on CD-ROM, enabling key word search and export of key information, addresses, phone numbers and executive names with titles for every company profiled. |
| clinical trial technology companies: Alzheimer's Disease Drug Development Jeffrey Cummings, Jefferson Kinney, Howard Fillit, 2022-03-31 Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models. |
| clinical trial technology companies: Personal Genome Medicine Michael J. Malinowski, 2023-08-31 Draws from the past and present of medicine in the U.S. to address the emerging future of personal genome medicine. |
| clinical trial technology companies: Pharmacology for the Surgical Technologist Katherine Snyder, Chris Keegan, 2016-02-24 Learn with the most trusted pharmacology text written specifically for surgical technologists! Pharmacology for the Surgical Technologist, 4th Edition ensures that as an integral member of the operating room team, you have an in-depth understanding of surgical medications. It covers everything from basic conversions, terminology, and calculations to anesthesia and medications used for perioperative care. This edition adds coverage of next-generation antibiotics, new technology in orthopedics, advances in cataract surgery, and more plus a full-color design and expanded art program. An Evolve companion website lets you practice drug calculations. Written by experienced Surgical Technology educators Katherine Snyder and Chris Keegan, this book covers all areas of pharmacology that are designated in the Core Curriculum for Surgical Technology, 6th Edition. Coverage of pharmacology meets the needs of the Surgical Technologist and includes all areas designated in the Core Curriculum for Surgical Technology, 6th Edition.Chapter study questions help you measure your knowledge and apply it to practice, and serve as a review tool for classroom and certification exams.Clinical features include Tech Tips from experts, Caution boxes with drug alerts to help prevent potential patient harm, and Notes simplifying difficult concepts.Insight boxes provide in-depth, cutting-edge information about a specific product, procedure, or process.Concise three-part organization makes it easier to understand 1) the foundations of pharmacology, mathematics, and drug administration, 2) applications of pharmacology to the surgical environment, and 3) preoperative medications, types of anesthesia, and emergency situations.Evolve companion website includes exercises allowing you to practice math calculations, as well as drug monographs from Mosby s Essential Drugs for Surgical Technology.Advanced Practice boxes provide information and advice on issues and applications that help you advance to the role of Surgical Assistant.Trusted authors Kathy Snyder and Chris Keegan bring more than 50 years of combined experience, and provide the information you need to succeed in the classroom, on the certification exam, and in the operating room.Learning Objectives in each chapter list the key content you should master and provide a useful study tool in preparing for examinations. NEW! Coverage of hot topics includes next-generation antibiotics, new technology involving orthopedic surgery, advances in cataract surgery, and more.NEW! Now in full color, an expanded art program helps you visualize concepts in anatomy and physiology, medications, equipment, and procedures.NEW! A comprehensive glossary supports key terms that are highlighted in the text.NEW! Make It Simple boxes review and break down medical terminology. |
| clinical trial technology companies: Drug Repurposing Ramarao Poduri, Gaurav Joshi, Mayank Sharma, Asim Kumar, 2023-10-04 Drug repurposing, or drug repositioning, or reprofiling, has emerged as a valid approach in modern drug discovery. The book describes tools and techniques for identifying new therapeutic potentials for existing drugs and covers the repurposing of drugs from synthetic and natural origin. It compares the costs of drug repurposing with traditional drug discovery and discusses challenges and future perspectives of drug repurposing. |
| clinical trial technology companies: Managing Cancer Patricia C. Walter, 2004-12 In the media and medical literature, managing cancer as a chronic disease is fast becoming the focus of care. Patients who manage their cancer have the best chance of staying alive, having a good quality of life, or of being cured. They seek second opinions, research all types of cancer treatments, ask the right questions, protect themselves against errors during treatment, and change their lifestyles. This book provides patients with more than 200 things they need to know and elaborates on more than 200 things they can do. Doing only a few of these things may save your life. This book teaches patients how to increase their odds, how to go about making treatment decisions, how to find what they need on the Internet, why research services are worth their weight in gold, and much more. Managing Cancer: Managing to Stay Alive gives patients the following: information about what to do first; forms to help keep track of medical information; lists of questions to use to evaluate treatment options (traditional, integrative, alternative, and experimental); questions to have answered before deciding on a treatment, when given a new medication, and before having a biopsy procedure; questions to ask conventional doctors, alternative doctors, the oncologist initially, and yourself before beginning a treatment; information on how to help avoid becoming one of the 50,000 Americans who die from medical errors in hospitals or one of the 100,000 patients who die from hospital infections each year; and concise listings of symptoms of medical emergencies such as infection, anemia, blood clotting problems, allergic reactions, and adverse reactions to drugs. |
| clinical trial technology companies: Healthcare Delivery Reform and New Technologies: Organizational Initiatives Guah, Matthew, 2010-11-30 Healthcare Delivery Reform and New Technologies: Organizational Initiatives contains cross-disciplinary research on strategic initiatives for healthcare reform that impact not only patients, but also organizations, healthcare providers, and policymakers. Contributions focus on the operational as well as theoretical aspects of healthcare management, healthcare delivery processes, and patient-centered initiatives. |
| clinical trial technology companies: Translational and Experimental Clinical Research Daniel P. Schuster, William J. Powers (MD.), 2005 This volume is a comprehensive textbook for investigators entering the rapidly growing field of translational and experimental clinical research. The book offers detailed guidelines for designing and conducting a study and analyzing and reporting results and discusses key ethical and regulatory issues. Chapters address specific types of studies such as clinical experiments in small numbers of patients, pharmacokinetics and pharmacodynamics, and gene therapy and pharmacogenomic studies. A major section describes modern techniques of translational clinical research, including gene expression, identifying mutations and polymorphisms, cloning, transcriptional profiling, proteomics, cell and tissue imaging, tissue banking, evaluating substrate metabolism, and in vivo imaging. |
| clinical trial technology companies: Zipes and Jalife's Cardiac Electrophysiology: From Cell to Bedside, E-Book Jose Jalife, William Gregory Stevenson, 2021-12-16 Fully updated from cover to cover, Zipes and Jalife's Cardiac Electrophysiology: From Cell to Bedside, 8th Edition, provides the comprehensive, multidisciplinary coverage you need—from new knowledge in basic science to the latest clinical advances in the field. Drs. José Jalife and William Gregory Stevenson lead a team of global experts who provide cutting-edge content and step-by-step instructions for all aspects of cardiac electrophysiology. - Packs each chapter with the latest information necessary for optimal basic research as well as patient care. - Covers new technologies such as CRISPR, protein research, improved cardiac imaging, optical mapping, and wearable devices. - Contains significant updates in the areas of molecular biology and genetics, iPSCs (induced pluripotent stem cells), embryonic stem cells, precision medicine, antiarrhythmic drug therapy, cardiac mapping with advanced techniques, and ablation technologies including stereotactic radioablation. - Includes 47 new chapters covering both basic science and clinical topics. - Discusses extensive recent progress in the understanding, diagnosis, and management of arrhythmias, including new clinical insights on atrial fibrillation and stroke prevention, new advances in the understanding of ventricular arrythmias in genetic disease, and advances in implantable devises and infection management. - Features 1,600 high-quality photographs, anatomic and radiographic images, electrocardiograms, tables, algorithms, and more., with additional figures, tables, and videos online. - Recipient of a 2018 Highly Commended award from the British Medical Association. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| clinical trial technology companies: Marketing of High-technology Products and Innovations Jakki J. Mohr, Sanjit Sengupta, Stanley F. Slater, 2010 This title provides a thorugh overview of the issues high-tech marketers must address, and provides a balance between conceptual discussions and examples; small and big business; products and services; and consumer and business-to-business marketing contexts. |
| clinical trial technology companies: Supply Chain Planning for Clinical Trials Ryan Mills, 2024-07-03 Ensure your clinical trial supply chain is running smoothly with this practical guide Clinical trials are a critical part of the pharmaceutical development process. These trials cannot proceed without timely and regular receipt of the drugs being tested, which can prove a challenge for drug manufacturers who have not yet established the structures required to produce quality-controlled specimens of the drug at scale. Managing supply chains of pre-production drugs for clinical trials is therefore an essential component of drug development. Supply Chain Planning for Clinical Trials offers a practical introduction to this process for researchers and industry professionals. Beginning with the basics of clinical trial supply chain management, it proceeds step by step through all aspects of demand and supply planning for clinical trials. The result is a thorough overview that also offers practical examples of how to plan supply for clinical trials. Supply Chain Planning for Clinical Trials readers will also find: Tools for minimizing risk and expense by optimizing the relationship between supply and demand Detailed discussion of topics including quality and regulatory considerations and the business processes that support clinical trial supply chain management Spreadsheet-based models to illustrate key concepts, adaptable to the readers’ specific scenarios Supply Chain Planning for Clinical Trails is ideal for pharmaceutical industry professionals involved in clinical trial supply planning, as well as academics and researchers interested in the pharmaceutical industry and its logistics. |
| clinical trial technology companies: Readings in Medical Artificial Intelligence William J. Clancey, Edward Hance Shortliffe, 1984 |
| clinical trial technology companies: Global Competitiveness of U.S. Advanced-technology Manufacturing Industries , 1991 |
ClinicalTrials.gov
Study record managers: refer to the Data Element Definitions if submitting registration or results information.
CLINICAL Definition & Meaning - Merriam-Webster
The meaning of CLINICAL is of, relating to, or conducted in or as if in a clinic. How to use clinical in a sentence.
CLINICAL | English meaning - Cambridge Dictionary
CLINICAL definition: 1. used to refer to medical work or teaching that relates to the examination and treatment of …
CLINICAL definition and meaning | Collins English Dict…
Clinical means involving or relating to the direct medical treatment or testing of patients.
Clinical Definition & Meaning | Britannica Dictionary
CLINICAL meaning: 1 : relating to or based on work done with real patients of or relating to the medical treatment that is given to patients in hospitals, …
ClinicalTrials.gov
Study record managers: refer to the Data Element Definitions if submitting registration or results information.
CLINICAL Definition & Meaning - Merriam-Webster
The meaning of CLINICAL is of, relating to, or conducted in or as if in a clinic. How to use clinical in a sentence.
CLINICAL | English meaning - Cambridge Dictionary
CLINICAL definition: 1. used to refer to medical work or teaching that relates to the examination and treatment of ill…. Learn more.
CLINICAL definition and meaning | Collins English Dictionary
Clinical means involving or relating to the direct medical treatment or testing of patients.
Clinical Definition & Meaning | Britannica Dictionary
CLINICAL meaning: 1 : relating to or based on work done with real patients of or relating to the medical treatment that is given to patients in hospitals, clinics, etc.; 2 : requiring treatment as a …
CLINICAL | meaning - Cambridge Learner's Dictionary
CLINICAL definition: 1. relating to medical treatment and tests: 2. only considering facts and not influenced by…. Learn more.
Clinical - definition of clinical by The Free Dictionary
1. pertaining to a clinic. 2. concerned with or based on actual observation and treatment of disease in patients rather than experimentation or theory. 3. dispassionately analytic; …
Clinical - Definition, Meaning & Synonyms | Vocabulary.com
Something that's clinical is based on or connected to the study of patients. Clinical medications have actually been used by real people, not just studied theoretically.
Clinical Definition & Meaning - YourDictionary
Clinical definition: Of, relating to, or connected with a clinic.
Equity Medical | Clinical Research In New York And Kentucky
We pioneer dermatological advancements, collaborating on innovative treatments through research and clinical trials in urban New York City and rural Southern Kentucky.
